| |
| Johnson & Johnson Commits to Joint Investment to Accelerate Rapid Manufacturing Scale-Up |
|
|
|
|
|
|
| Catalent today announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing of Johnson & Johnson’s lead vaccine candidate for COVID-19.
Under the terms of the agreement, both parties will commit joint investment to accelerate rapid scale-up of segregated manufacturing capacity on a new vial filling line at its Bloomington, Indiana biologics facility. Catalent also plans to hire approximately 300 additional employees at the site for this program starting in July 2020. |
|
|
|
| | |
|
|
| |
| Every brand has a challenge. We have a solution. |
| | | | or call +1 877 891 9609 to speak with one of our experts today! |
| | |
|
|
|
|
|
| |
| To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at [email protected], or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
|
|
 |
